Drug Profile
Research programme: influenza vaccines - GlaxoSmithKline/Shenzhen Neptunus Interlong Bio-Technique
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator GlaxoSmithKline; Shenzhen Neptunus Interlong Bio-Technique
- Developer GSK; Shenzhen Neptunus Interlong Bio-Technique
- Class Influenza virus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Influenza virus infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Influenza-virus-infections in China
- 16 Jul 2016 No recent reports of development identified for research development in Influenza-virus-infections in Hong Kong
- 16 Jul 2016 No recent reports of development identified for research development in Influenza-virus-infections in Macau